Pure Global
NCT06336291

A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence

A Dose Optimization Study for L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
Philogen S.p.A.·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Glioblastoma
Drug/Device/Intervention
L19TNF
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Philogen S.p.A.
Timeline & enrollment
Phase
Phase 2
Start date
Jun 01, 2024
End date
Jun 01, 2026
Enrollment
90 participants
Primary outcome

Adverse Events,Serious Adverse Events,Unacceptable Toxicity,DILI assessment,Survival

Summary

The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and
 pharmacodynamic information of the combination of L19TNF and lomustine at different dose
 levels in patients with Glioblastoma at progression or recurrence

ICD-10 classifications
Malignant neoplasm of brainMalignant neoplasm: Brain, unspecifiedMesotheliomaMalignant neoplasm: Brain stemMalignant neoplasm: Overlapping lesion of brain
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06336291
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06336291 through Pure Global AI's free database. This Phase 2 trial is sponsored by Philogen S.p.A. and is currently Not yet recruiting. The study focuses on Glioblastoma. Target enrollment is 90 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.